Biotech RadarJobs updated

COMPANY

Vericel

HQ: Burlington, MA source · vcel.com ↗

FDA-approved therapeutic company Clinical Phase 3

17 open jobs · last seen Oct 23, 2026 · 15 sources

Location: Burlington, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Articular Cartilage Defect Chondral Defect Dilated Cardiomyopathy Articular Cartilage Osteochondritis Dissecans Articular Cartilage Disorder of Knee Critical Limb Ischemia Ischemic Dilated Cardiomyopathy Single Level Posterolateral Spinal Fusion Ununited Fracture Pseudarthrosis Cartilage Diseases Peripheral Arterial Disease Osteonecrosis Ixmyelocel-T Carticel (autologous cultured chondrocyte) implantation

17Open jobs14Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
UK Commercialization ManagerLondon, City of, GBOct 22, 2026Oct 23, 2026
Senior Medical Director, UK & EuropeLondon, City of, GBOct 22, 2026Oct 23, 2026
HR Operations & Total Rewards ManagerBurlington, MA, USOct 21, 2026Oct 21, 2026
Manufacturing Compliance Specialist IBurlington, MA, USOct 17, 2026Oct 17, 2026
Associate I, Cell Therapy ManufacturingBurlington, MA, USOct 9, 2026Oct 11, 2026

See all 17 jobs

Timeline

  1. Trial start Phase 3: A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle source ↗
  2. Grant Government contract: $197M (up to, as announced), announced Apr 2, 2026. Source: company release on GlobeNewswire. source ↗
  3. Trial start Phase 3: A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee source ↗
  4. Trial start Phase 2: An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (I source ↗
  5. Trial start Phase 3: An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) source ↗
  6. Trial start —: Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee source ↗
  7. Trial start Phase 2: Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy source ↗
  8. Trial start Phase 2: Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) source ↗
  9. Trial start Phase 3: Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee source ↗
  10. Trial start Phase 3: Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head source ↗
  11. Trial start Phase 2: Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia source ↗
  12. Trial start Phase 1/Phase 2: Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion source ↗
  13. Trial start Phase 1/Phase 2: Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures. source ↗
  14. Trial start Phase 4: Study of the Treatment of Articular Repair (STAR) source ↗
  15. Trial start —: The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Clinical trials (lead sponsor) 14

RecordTitlePhaseStatusStartPrimary completion
NCT03588975A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the KneePhase 3RecruitingOct 24, 20182030-02 (estimated)
NCT06915233A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the AnklePhase 3RecruitingMay 28, 20262030-07 (estimated)
NCT01483898An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)Phase 3Completed2012-02Mar 25, 2014 (actual)
NCT01670981An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)Phase 2CompletedFeb 20, 2013Feb 1, 2016 (actual)
NCT00765518Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)Phase 2Completed2008-09Sep 5, 2012 (actual)
NCT01020968Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated CardiomyopathyPhase 2Completed2009-12Jan 11, 2012 (actual)
NCT00719576Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the KneePhase 3Completed2008-072012-03 (actual)
NCT01251588Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the KneeNot listedCompleted2010-122015-03 (actual)
NCT00797550Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine FusionPhase 1/Phase 2Terminated2006-042006-08 (actual)
NCT00424567Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.Phase 1/Phase 2Terminated2003-10Not listed
NCT00158613Study of the Treatment of Articular Repair (STAR)Phase 4Completed2000-032005-11 (actual)
NCT00140634The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry PatientsNot listedCompleted1995-032009-01 (actual)
NCT00468000Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb IschemiaPhase 2Completed2007-042011-03 (actual)
NCT00505219Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral HeadPhase 3Completed2007-092010-09 (actual)

Open jobs 17

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
UK Commercialization ManagerLondon, City of, GBOct 22, 2026Oct 23, 2026Not stated
Senior Medical Director, UK & EuropeLondon, City of, GBOct 22, 2026Oct 23, 2026Not stated
HR Operations & Total Rewards ManagerBurlington, MA, USOct 21, 2026Oct 21, 2026Not stated
Manufacturing Compliance Specialist IBurlington, MA, USOct 17, 2026Oct 17, 2026Not stated
Associate I, Cell Therapy ManufacturingBurlington, MA, USOct 9, 2026Oct 11, 2026Entry
Senior Director, Quality ControlBurlington, MA, USSep 30, 2026Oct 11, 2026Senior
Customer Care Associate IBurlington, MA, USSep 25, 2026Oct 11, 2026Entry
Associate Production SchedulerBurlington, MA, USSep 24, 2026Oct 11, 2026Mid
Senior Specialist, Commercial LogisticsBurlington, MA, USSep 21, 2026Oct 11, 2026Senior
Sr. Manager, Promotional Planning & Marketing OperationsBurlington, MA, USSep 4, 2026Oct 11, 2026Senior
Senior Financial AnalystBurlington, MA, USSep 4, 2026Oct 11, 2026Senior
Director, Human ResourcesBurlington, MA, USAug 28, 2026Oct 11, 2026Senior
Director, Facilities & EngineeringCambridge, MA, USAug 18, 2026Oct 11, 2026Senior
Senior Medical Science Liaison - Orthopedics NortheastUSAug 10, 2026Oct 11, 2026Senior
CRM Systems Manager, ITBurlington, MA, USAug 1, 2026Oct 11, 2026Senior
Quality Control Analyst, IIBurlington, MA, USApr 17, 2026Oct 11, 2026Mid
Materials Associate, IIBurlington, MA, USApr 3, 2026Oct 11, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Vericel on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback